News Release

Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams

SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a sales and marketing plan for the anticipated launch of its epinephrine pre-filled syringe for treatment of allergic reactions (Type I) including anaphylaxis.

Dragana Males, M.D. has joined Adamis as a Medical Director. In this role, she will work closely with other senior management members to oversee all aspects of clinical development. Most recently, she served as Drug Safety Physician within the Medical Services Group of Product Safety and Risk Management at Mylan Inc., the parent of the marketer and distributor of EpiPen®. Prior to Mylan, she spent several years in various clinical research director roles. She was a medical director at Boehringer Ingelheim Pharma for ten years developing clinical programs and protocol designs for phase III and IV studies. As a pulmonologist, she brings a wealth of knowledge which includes protocol development, study design, drug safety, medical monitoring, investigator recruitment, study management, and the development and delivery of medical education programs.

Jennifer C. Suski has joined Adamis as Senior Director of Marketing. Most recently, she was Director of Marketing for Santarus Inc., a specialty biopharmaceutical company which was acquired by Salix Pharmaceuticals for $2.6 billion earlier this year. While at Santarus, she led their Marketing Department through three new product launches and one product re-launch, resulting in annual product revenue of nearly $400 million. With thirteen years of pharmaceutical industry experience, she will spearhead marketing efforts for Adamis focusing on areas such as market research, advertising, brand planning and lifecycle management for all products.

Joshua D. Seno has also joined Adamis from Santarus as Senior Director of Commercial Affairs bringing over 12 years of commercial experience with him. In his last role, as Director of Market Research & Forecasting for Santarus, Inc., he led all primary and secondary market research, conducted ongoing commercial analytics, and developed the company's brand forecasting for all five of its commercial products. Before Santarus, Inc. he spent seven years in business development roles with Amylin Pharmaceuticals where he contributed to the successful launches of Byetta and Symlin.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, "We are very excited to have such talented professionals join the Adamis team as we prepare to launch our first commercial product and begin registrational clinical trials for our respiratory products. Dr. Males has a wealth of clinical research, trial design and protocol management knowledge that will benefit Adamis immeasurably. Additionally, both Jennifer Suski and Joshua Seno's marketing and commercial expertise will immediately provide Adamis the foundation for launching its first product."

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.

Adamis Contact

Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951